Vertex Pharmaceuticals (VRTX) Capital Leases (2011 - 2025)
Vertex Pharmaceuticals' quarterly Capital Leases came in at $111.4 million in Q1 2025, down 69.18% year-on-year from $361.5 million in Q1 2024, and down 1.24% quarter-over-quarter from $112.8 million in Q4 2024.
Vertex Pharmaceuticals has reported Capital Leases for 15 years, with the latest figure at $111.4 million in Q1 2025.
- For the quarter ending Q1 2025, Capital Leases fell 69.18% year-over-year to $111.4 million; the trailing twelve-month figure through Mar 2025 stood at $111.4 million (down 69.18% YoY), and the FY2024 full-year result was $112.8 million, down 70.01% from the prior year.
- Capital Leases for Q1 2025 stood at $111.4 million, down from $112.8 million in the prior quarter.
- The five-year high for Capital Leases was $530.3 million in Q1 2021, with the low at $111.4 million in Q1 2025.
- Average Capital Leases over 5 years is $386.1 million, with a median of $417.6 million recorded in 2023.
- Year-over-year, Capital Leases rose 0.55% in 2021 and sank 70.79% in 2024.
- Tracing VRTX's Capital Leases over 5 years: stood at $509.8 million in 2021, then retreated by 15.5% to $430.8 million in 2022, then slipped by 12.7% to $376.1 million in 2023, then slumped by 70.01% to $112.8 million in 2024, then dropped by 1.24% to $111.4 million in 2025.
- The last three Capital Leases figures came in at $111.4 million (Q1 2025), $112.8 million (Q4 2024), and $114.0 million (Q3 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 111.40 Mn |
| Dec 31, 2024 | 112.80 Mn |
| Sep 30, 2024 | 114.00 Mn |
| Jun 30, 2024 | 346.60 Mn |
| Mar 31, 2024 | 361.50 Mn |
| Dec 31, 2023 | 376.10 Mn |
| Sep 30, 2023 | 390.30 Mn |
| Jun 30, 2023 | 404.10 Mn |
| Mar 31, 2023 | 417.60 Mn |
| Dec 31, 2022 | 430.80 Mn |
| Sep 30, 2022 | 442.30 Mn |
| Jun 30, 2022 | 482.30 Mn |
| Mar 31, 2022 | 495.50 Mn |
| Dec 31, 2021 | 509.80 Mn |
| Sep 30, 2021 | 513.26 Mn |
| Jun 30, 2021 | 524.93 Mn |
| Mar 31, 2021 | 530.33 Mn |
| Dec 31, 2020 | 539.00 Mn |
| Sep 30, 2020 | 546.51 Mn |
| Jun 30, 2020 | 522.07 Mn |
| Mar 31, 2020 | 532.95 Mn |
| Dec 31, 2019 | 538.58 Mn |
| Sep 30, 2019 | 541.56 Mn |
| Jun 30, 2019 | 551.53 Mn |
| Mar 31, 2019 | 560.38 Mn |
| Dec 31, 2018 | 561.89 Mn |
| Sep 30, 2018 | 15.14 Mn |
| Jun 30, 2018 | 15.03 Mn |
| Mar 31, 2018 | 16.91 Mn |
| Dec 31, 2017 | 563.41 Mn |
| Sep 30, 2017 | 20.26 Mn |
| Jun 30, 2017 | 25.35 Mn |
| Mar 31, 2017 | 498.78 Mn |
| Dec 31, 2016 | 486.36 Mn |
| Sep 30, 2016 | 473.07 Mn |
| Jun 30, 2016 | 34.32 Mn |
| Mar 31, 2016 | 38.89 Mn |
| Dec 31, 2015 | 472.61 Mn |
| Sep 30, 2015 | 472.72 Mn |
| Jun 30, 2015 | 472.83 Mn |
| Mar 31, 2015 | 472.97 Mn |
| Dec 31, 2014 | 39.29 Mn |
| Sep 30, 2014 | 473.17 Mn |
| Jun 30, 2014 | 45.05 Mn |
| Mar 31, 2014 | 473.36 Mn |
| Dec 31, 2013 | 48.75 Mn |
| Sep 30, 2013 | 392.57 Mn |
| Jun 30, 2013 | 28.09 Mn |
| Mar 31, 2013 | 316.82 Mn |
| Dec 31, 2012 | 268.03 Mn |
| Sep 30, 2012 | 215.96 Mn |
| Jun 30, 2012 | 160.29 Mn |
| Mar 31, 2012 | 94.18 Mn |
| Sep 30, 2011 | 25.47 Mn |